• Je něco špatně v tomto záznamu ?

Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party

K. Hirschbühl, M. Labopin, M. Houhou, L. Gabellier, H. Labussière-Wallet, B. Lioure, D. Beelen, J. Cornelissen, G. Wulf, P. Jindra, H. Tilly, J. Passweg, R. Niittyvuopio, G. Bug, C. Schmid, A. Nagler, S. Giebel, M. Mohty

. 2021 ; 56 (5) : 1190-1199. [pub] 20201209

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21025766
E-zdroje Online Plný text

NLK Free Medical Journals od 1997 do Před 1 rokem
Freely Accessible Science Journals od 1997 do Před 1 rokem
ProQuest Central od 2000-01-01 do Před 1 rokem
Open Access Digital Library od 1997-01-01
Health & Medicine (ProQuest) od 2000-01-01 do Před 1 rokem

Odkazy

PubMed 33293597
DOI 10.1038/s41409-020-01173-x
Knihovny.cz E-zdroje

Second- and third-generation tyrosine kinase inhibitors (TKI) play an important role in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL). However, data on feasibility and efficacy of using these drugs for persisting or relapsed Ph + ALL after allogeneic stem cell transplantation (alloSCT) are scarce. Based on the EBMT Acute Leukemia Working Party registry, we evaluated the use of second-/third-generation TKI in 140 patients with Ph + ALL, suffering from measurable residual disease (MRD, n = 6), molecular relapse (MRel, n = 23), or hematological relapse (HRel, n = 111) following alloSCT. Treatment included dasatinib in 104, nilotinib in 18, or ponatinib in 18 patients. Forty-nine patients received TKI monotherapy, while 91 received additional treatment. Toxicity of second-/third-generation TKI post alloSCT was comparable to pretransplant use and could be managed with dose reduction or temporary discontinuation. Response rates were 71% (overall) and 61% (following TKI monotherapy). For the entire cohort, 2- and 5-year overall survival (OS) was 49% and 33%, respectively. OS was comparable among patients treated for persisting MRD/MRel and HRel. Among patients treated with TKI monotherapy, 2- and 5-year OS was 38% and 33%, respectively. The data underscore that second-/third-generation TKI are important compounds for the management of active Ph + ALL post alloSCT.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025766
003      
CZ-PrNML
005      
20240528151358.0
007      
ta
008      
211013s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41409-020-01173-x $2 doi
035    __
$a (PubMed)33293597
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Hirschbühl, Klaus $u Department Hematology and Oncology, Medical Faculty, University of Augsburg, Augsburg, Germany
245    10
$a Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party / $c K. Hirschbühl, M. Labopin, M. Houhou, L. Gabellier, H. Labussière-Wallet, B. Lioure, D. Beelen, J. Cornelissen, G. Wulf, P. Jindra, H. Tilly, J. Passweg, R. Niittyvuopio, G. Bug, C. Schmid, A. Nagler, S. Giebel, M. Mohty
520    9_
$a Second- and third-generation tyrosine kinase inhibitors (TKI) play an important role in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL). However, data on feasibility and efficacy of using these drugs for persisting or relapsed Ph + ALL after allogeneic stem cell transplantation (alloSCT) are scarce. Based on the EBMT Acute Leukemia Working Party registry, we evaluated the use of second-/third-generation TKI in 140 patients with Ph + ALL, suffering from measurable residual disease (MRD, n = 6), molecular relapse (MRel, n = 23), or hematological relapse (HRel, n = 111) following alloSCT. Treatment included dasatinib in 104, nilotinib in 18, or ponatinib in 18 patients. Forty-nine patients received TKI monotherapy, while 91 received additional treatment. Toxicity of second-/third-generation TKI post alloSCT was comparable to pretransplant use and could be managed with dose reduction or temporary discontinuation. Response rates were 71% (overall) and 61% (following TKI monotherapy). For the entire cohort, 2- and 5-year overall survival (OS) was 49% and 33%, respectively. OS was comparable among patients treated for persisting MRD/MRel and HRel. Among patients treated with TKI monotherapy, 2- and 5-year OS was 38% and 33%, respectively. The data underscore that second-/third-generation TKI are important compounds for the management of active Ph + ALL post alloSCT.
650    _2
$a dospělí $7 D000328
650    12
$a transplantace hematopoetických kmenových buněk $7 D018380
650    _2
$a lidé $7 D006801
650    _2
$a filadelfský chromozom $7 D010677
650    12
$a akutní lymfatická leukemie $x terapie $7 D054198
650    _2
$a inhibitory proteinkinas $x terapeutické užití $7 D047428
650    _2
$a recidiva $7 D012008
650    _2
$a registrace $7 D012042
655    _2
$a časopisecké články $7 D016428
700    1_
$a Labopin, Myriam $u Service d'Hématologie et de Thérapie cellulaire, Hôpital Saint Antoine, ALWP Office (EBMT), Paris, France
700    1_
$a Houhou, Mohamed $u Service d'Hématologie et de Thérapie cellulaire, Hôpital Saint Antoine, ALWP Office (EBMT), Paris, France
700    1_
$a Gabellier, Ludovic $u Département d'Hématologie Clinique, CHU Lapeyronie, Montpellier, France
700    1_
$a Labussière-Wallet, Hélène $u Centre Hospitalier Lyon Sud, Service Hematologie, Lyon, France
700    1_
$a Lioure, Bruno $u Nouvel Hopital Civil, Strasbourg, France
700    1_
$a Beelen, Dietrich $u Department of Bone Marrow Transplantation, University Hospital Essen, Essen, Germany
700    1_
$a Cornelissen, Jan $u Department of Hematology, Erasmus MC Cancer Institute University Medical Center Rotterdam, Rotterdam, The Netherlands
700    1_
$a Wulf, Gerald $u Abteilung Hämatologie und Onkologie, Universitätsklinikum Göttingen, Göttingen, Germany
700    1_
$a Jindra, Pavel $u Department of Hematology/Oncology, Charles University Hospital, Pilsen, Czech Republic
700    1_
$a Tilly, Hervé $u Department of Hematology, Centre Henri Becquerel, Rouen, France
700    1_
$a Passweg, Jakob $u Department of Hematology, University Hospital of Basel, Basel, Switzerland
700    1_
$a Niittyvuopio, Riita $u HUCH Comprehensive Cancer Center, Stem Cell Transplantation Unit, Helsinki, Finland
700    1_
$a Bug, Gesine $u Universitätsklinikum Frankfurt, Medizinische Klinik II, Frankfurt, Germany
700    1_
$a Schmid, Christoph $u Department Hematology and Oncology, Medical Faculty, University of Augsburg, Augsburg, Germany. christoph.schmid@uk-augsburg.de
700    1_
$a Nagler, Arnon $u Department of Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer and Tel-Aviv University, Tel Aviv, Israel
700    1_
$a Giebel, Sebastian $u Department of Bone Marrow Transplantation and Oncology/Hematology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland
700    1_
$a Mohty, Mohamad $u Service d'Hématologie et de Thérapie cellulaire, Hôpital Saint Antoine, ALWP Office (EBMT), Paris, France $7 xx0317729
773    0_
$w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 56, č. 5 (2021), s. 1190-1199
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33293597 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20240528151354 $b ABA008
999    __
$a ok $b bmc $g 1714689 $s 1146273
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 56 $c 5 $d 1190-1199 $e 20201209 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace